• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager
• BL Club
• Smartbuy

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

We recommend a buy in Ranbaxy Laboratories from a short-term perspective. It is evident from the charts of Ranbaxy that it has been on an intermediate-term downtrend from its June high of Rs 613. This downtrend accelerated in the early part of September triggered by negative news flow. In September alone, the stock tumbled more than 50 per cent. However, the stock found support at around Rs 240, which is a significant long-term support level. On October 8, the stock experienced bullish momentum by gaining 9 per cent accompanied with high volume. Both the daily and weekly relative strength index have recovered from deep oversold territory. We take a contrarian view on the stock for the short-term and anticipate a corrective up move until it hits our price target of Rs 308 in the impending trading sessions. Traders with short-term perspective can buy the stock while maintaining a stop-loss at Rs 265.

Yoganand D.

More Stories on : Stocks | Recommendation | Ranbaxy Laboratories Ltd | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line